Nilotinib i dazatinibv 1-y linii terapii bol'nykhkhronicheskim mieloleykozomv khronicheskoy faze

by N S Lazorko, E G Lomaia, E I Sbityakova, A Yu Zaritskiy
Published 2011-06-01

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia

by E. G. Lomaia, E. G. Romanova, E. I. Sbityakova, A. Yu. Zaritskiy
Published 2014-07-01

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia

by E. G. Lomaia, E. G. Romanova, E. I. Sbityakova, A. Yu. Zaritskiy
Published 2014-07-01

Change of concentration of biochemical markers of dysfunction of endothelium at intake of inhibitors of tyrosinekinase of I and II generations at patients with a chronic myeloid le...

by K. V. Naumova, I. L. Davydkin, E. G. Lomaia, T. Yu. Stepanova, T. P. Kuzmina, D. B. Zammoyeva
Published 2021-01-01

Quality of life, symptom profile and clinical efficacy of second-line treatment with dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia: results...

by T. I. Ionova, T. P. Nikitina, E. G. Lomaia, G. B. Kuchma, E. R. Machyulaytene, E. I. Usacheva, T. V. Shnaider, A. Yu. Rodionova, K. A. Kurbatova
Published 2015-10-01

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS

by E. G. lisina, N. T. Siordiya, P. A. Butylin, A. A. Silyutina, N. M. Matyukhina, O. M. Senderova, E. S. Fokina, V. A. Ovsepyan, E. G. Lomaia, A. Yu. Zaritskiy
Published 2017-10-01

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases

by A L MELIKYAN, I N SUBORTSEVA, E A GILYAZITDINOVA, T I KOLOSHEJNOVA, E I PUSTOVAYA, E K EGOROVA, A M KOVRIGINA, A B SUDARIKOV, A O ABDULLAEV, E G LOMAIA, N T SIORDIYA, A Yu ZARITSKEY, V G SAVCHENKO
Published 2018-07-01